Table 3 Costs, number of patient visits and test turnaround time of different screening strategies
Strategy | Contingent cfDNA screening | Reflex cfDNA screening | Primary cfDNA screening | |||
|---|---|---|---|---|---|---|
Risk cut-off(s) of eFTS | 1 in 1000 | 1 in 1000 | 1 in 1000 | 1 in 50 and 1 in 1000 | ||
cfDNA screening technology | Sequencing | Sequencing | RCA/Imaging solution | RCA/Imaging solution | Sequencing | RCA/Imaging solution |
Costs (CAD) | ||||||
 Total program | $20,053,297 | $18,759,518 | $18,132,468 | $20,059,786 | $43,165,976 | $41,743,817 |
 Per woman screening | $201 | $188 | $181 | $201 | $432 | $417 |
 Per case of T21 diagnosed prenatally | $82,005 | $76,529 | $74,112 | $81,169 | $161,305 | $159,510 |
 Per case of T21 diagnosed prenatally (all cfDNA screening no-call have a PND) | $81,998 | $76,691 | $74,149 | $81,455 | $167,680 | $162,167 |
 Per additional case of T21 diagnosed compared to the contingent cfDNA screening | – | – | – | $3799 | $1,795,639 | $1,687,537 |
Number of patient visit and turnaround time | ||||||
 Number of visit (1st cfDNA screening has result) | 3 | 1 | 1 | 1 | 1 | 1 |
 Number of visit (1st cfDNA screening no-call result) | 4 | 1 | 1 | 1 | 2 | 1 |
 Days from initial sample received to cfDNA screening result (1st cfDNA screening has result) | 16 | 13 | 7 | 7 | 10 | 4 |
 Days from initial sample received to cfDNA screening result (1st cfDNA screening no-call result) | 26 | 13 | 7 | 7 | 20 | 4 |